Section 1691.8 - Confidentiality(a)Maintenance.--The team shall maintain the confidentiality of any identifying information obtained relating to the death of an individual or adverse incidents regarding medication, including the name of the individual, guardians, family members, caretakers or alleged or suspected perpetrators of abuse, neglect or a criminal act.(b) Agreement.--Each member of the team and any person appearing before the team shall sign a confidentiality agreement applicable to all proceedings and reviews conducted by the team.(c) Liability.--An individual or agency that in good faith provides information or records to the team shall not be subject to civil or criminal liability as a result of providing the information or record.(d) Discovery.--The proceedings, deliberations and records of the team are privileged and confidential and shall not be subject to the act of February 14, 2008 (P.L.6, No.3), known as the Right-to-Know Law, discovery, subpoena or introduction into evidence in any civil or criminal action.(e)Meetings.--Meetings of the team at which a specific death is discussed shall be closed to the public and shall not be subject to the provisions of 65 Pa.C.S. Ch. 7 (relating to open meetings).(f)Attendance.--Nothing in this act shall prevent the team from allowing the attendance of a person with information relevant to a review at a medication death and incident team review meeting.(g) Penalty.--A person who violates the provisions of this section commits a misdemeanor of the third degree.Amended by P.L. TBD 2020 No. 126, § 1, eff. 2/23/2021.Added by P.L. 1198 2012 No. 148, § 8, eff. 1/22/2013.